Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab withdrawal-retreatment study in non-radiographic axial spondyloarthritis remission
2022-001153-23Phase 4Active
- Sponsor
- Novartis
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Secukinumab continuation with Placebo withdrawal (2 arms). Started Sep 2022; status: active.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2022-001153-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001153-23.